Trio-话题@MedSci

#Trio#

12篇内容 | 654人围观

关注话题

话题活跃用户

#插入话题

插入图片

最新最热

[GetTopicListResponse(id=1796478, encodeId=95451e964788d, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion收到CHMP对首批推荐用于治疗新冠肺炎的单克隆抗体之一瑞丹维单抗(CT-P59)的肯定意见, objectType=article, longId=220399, objectId=c27f220399db, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c27f220399db, replyNumber=0, likeNumber=93, createdTime=2022-03-12, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c27f220399db, moduleTitle=Celltrion收到CHMP对首批推荐用于治疗新冠肺炎的单克隆抗体之一瑞丹维单抗(CT-P59)的肯定意见, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c27f220399db)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796477, encodeId=021e1e96477f3, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Lancet：肾动脉超声消融治疗难治性高血压效果明显（RADIANCE-HTN TRIO研究）, objectType=article, longId=214816, objectId=bc212148160f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=bc212148160f, replyNumber=0, likeNumber=94, createdTime=2021-11-25, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=bc212148160f, moduleTitle=Lancet：肾动脉超声消融治疗难治性高血压效果明显（RADIANCE-HTN TRIO研究）, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=bc212148160f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796476, encodeId=dead1e9647620, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性, objectType=article, longId=214479, objectId=3d532144e904, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3d532144e904, replyNumber=0, likeNumber=70, createdTime=2021-11-26, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3d532144e904, moduleTitle=Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3d532144e904)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796480, encodeId=eb9e1e9648075, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Expression of microRNA-145,OCT4,and SOX2 in double primary endometrioid endometrial and ovarian carcinomas, objectType=article, longId=221054, objectId=c6e022105448, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=c6e022105448, replyNumber=0, likeNumber=58, createdTime=2022-07-28, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=c6e022105448, moduleTitle=Expression of microRNA-145,OCT4,and SOX2 in double primary endometrioid endometrial and ovarian carcinomas, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=c6e022105448)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796479, encodeId=247f1e96479cd, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎, objectType=article, longId=220524, objectId=62c1220524a2, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=62c1220524a2, replyNumber=0, likeNumber=65, createdTime=2022-01-24, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=62c1220524a2, moduleTitle=Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=62c1220524a2)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796475, encodeId=c32a1e96475e4, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, objectType=article, longId=212850, objectId=8a1421285025, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=8a1421285025, replyNumber=0, likeNumber=104, createdTime=2021-08-19, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=8a1421285025, moduleTitle=Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=8a1421285025)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796474, encodeId=4eb11e96474b4, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion的COVID-19治療抗體CT-P59已完成全球臨床試驗，立即向韓國食藥署申請緊急使用許可並在全球展開申請程序, objectType=article, longId=205366, objectId=4cee2053663b, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=4cee2053663b, replyNumber=0, likeNumber=66, createdTime=2021-02-16, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=4cee2053663b, moduleTitle=Celltrion的COVID-19治療抗體CT-P59已完成全球臨床試驗，立即向韓國食藥署申請緊急使用許可並在全球展開申請程序, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=4cee2053663b)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796473, encodeId=2e1b1e9647310, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, objectType=article, longId=183993, objectId=3c02183993a4, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=3c02183993a4, replyNumber=0, likeNumber=93, createdTime=2020-09-03, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=3c02183993a4, moduleTitle=欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=3c02183993a4)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796472, encodeId=89c91e9647266, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=JCI Insight：TRIOBP-5能够塑造静纤毛根并强化支持细胞从而实现听力功能, objectType=article, longId=175037, objectId=204b1e50374a, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=204b1e50374a, replyNumber=0, likeNumber=85, createdTime=2019-10-25, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=204b1e50374a, moduleTitle=JCI Insight：TRIOBP-5能够塑造静纤毛根并强化支持细胞从而实现听力功能, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=204b1e50374a)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796471, encodeId=ca501e964713e, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功, objectType=article, longId=162030, objectId=356d1620300f, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=356d1620300f, replyNumber=0, likeNumber=71, createdTime=2019-07-10, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=356d1620300f, moduleTitle=Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=356d1620300f)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796470, encodeId=b0e81e9647075, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Celltrion选用Oracle健康科学安全解决方案帮助成本效益型救命药物和生物仿制药上市, objectType=article, longId=115673, objectId=61a61156e380, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=61a61156e380, replyNumber=0, likeNumber=88, createdTime=2018-05-05, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=61a61156e380, moduleTitle=Celltrion选用Oracle健康科学安全解决方案帮助成本效益型救命药物和生物仿制药上市, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=61a61156e380)], followStatus=false, userIsMember=false, type=1, lengthMark=0), GetTopicListResponse(id=1796469, encodeId=7a0d1e9646970, content=<a href='/topic/show?id=c6051e82765' target=_blank style='color:#2F92EE;'>#Trio#</a>, objectTitle=Nature：鉴定出新的细菌DNA复制起始点元件DnaA-trio, objectType=article, longId=70415, objectId=59ffe04154c, topicUrl=null, isHasObj=0, objectCover=null, objectUrl=/article/show_article.do?id=59ffe04154c, replyNumber=0, likeNumber=135, createdTime=2016-11-08, rootId=0, userName=12498710m11暂无昵称, userId=f6142500060, projectId=1, avatar=, status=1, hasArticle=1, attachment=null, ipAttribution=, moduleDTOList=[ModuleDTO(moduleId=59ffe04154c, moduleTitle=Nature：鉴定出新的细菌DNA复制起始点元件DnaA-trio, moduleType=article, hrefUrl=https://www.medsci.cn/article/show_article.do?id=59ffe04154c)], followStatus=false, userIsMember=false, type=1, lengthMark=0)] 梅斯话题小助手

Trio

2020-05-29

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion收到CHMP对首批推荐用于治疗新冠肺炎的单克隆抗体之一瑞丹维单抗(CT-P59)的肯定意见

2022-03-12

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Lancet：肾动脉超声消融治疗难治性高血压效果明显（RADIANCE-HTN TRIO研究）

2021-11-25

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion的新冠肺炎单克隆抗体治疗药物瑞丹维单抗对德尔塔变异株显示出强效中和活性

2021-11-26

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Expression of microRNA-145,OCT4,and SOX2 in double primary endometrioid endometrial and ovarian carcinomas

2022-07-28

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion的单克隆抗体药物瑞丹维单抗获欧盟委员会批准用于治疗新冠肺炎

2022-01-24

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion发布抗COVID-19单克隆抗体治疗瑞丹维单抗(CT-P59)全球III期试验的阳性顶线结果

2021-08-19

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion的COVID-19治療抗體CT-P59已完成全球臨床試驗，立即向韓國食藥署申請緊急使用許可並在全球展開申請程序

2021-02-16

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

欧洲委员会批准Celltrion的英夫利昔单抗皮下制剂仿制药Remsima SC，用于治疗类风湿性关节炎

2020-09-03

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

JCI Insight：TRIOBP-5能够塑造静纤毛根并强化支持细胞从而实现听力功能

2019-10-25

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion Healthcare的皮下制剂CT-P13（英夫利昔单抗生物仿制药）治疗克罗恩病1期临床研究成功

2019-07-10

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Celltrion选用Oracle健康科学安全解决方案帮助成本效益型救命药物和生物仿制药上市

2018-05-05

12498710m11暂无昵称 (审核中...)

前往app查看评论内容

#Trio#

Nature：鉴定出新的细菌DNA复制起始点元件DnaA-trio

2016-11-08

科室
- - 订阅+
  - 更多科室
工具
服务